Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | LRRK2 | Q5S007 | 8/20 | 0.47 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.45 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2166135 | 1.00 | KMT2A (0.47) | KMT2ASMN1; SMN2LRRK2CCR5USP2 | |
| SCHEMBL1783943 | 1.00 | KMT2A (0.47) | KMT2ASMN1; SMN2LRRK2CCR5USP2 | |
| SCHEMBL2167258 | 0.90 | LRRK2 (0.46) | LRRK2CCR5USP2LMNAUSP28 | |
| SCHEMBL12403885 | 0.90 | LRRK2 (0.46) | LRRK2CCR5USP2LMNAUSP28 | |
| SCHEMBL12293726 | 0.90 | CCR5 (0.47) | SMN1; SMN2LRRK2CCR5USP2LMNA | |
| SCHEMBL15148415 | 0.90 | LRRK2 (0.46) | LRRK2CCR5USP2LMNAUSP28 | |
| SCHEMBL1355279 | 0.88 | HTT (0.50) | SMN1; SMN2LRRK2CCR5USP2LMNA | |
| Racephedrine SCHEMBL2168179 | 0.87 | CCR5 (0.44) | KMT2ALRRK2CCR5USP2LMNA | |
| Racephedrine SCHEMBL2168767 | 0.87 | CCR5 (0.44) | KMT2ALRRK2CCR5USP2LMNA | |
| SCHEMBL724611 | 0.86 | NPSR1 (0.46) | SMN1; SMN2LRRK2CCR5USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722920-B2 | Process for obtaining 3, 3-diphenylpropylamines | CRYSTAL PHARMA S.A.U. (ES) | 2014-05-13 | — | — | US | disclosed |
| US-8722920-B2 | Process for obtaining 3, 3-diphenylpropylamines | CRYSTAL PHARMA S.A.U. (ES) | 2014-05-13 | — | — | US | disclosed |
| EP-2281801-B1 | Process for obtaining 3,3-diphenylpropylamines | CRYSTAL PHARMA SAU (ES) | 2014-01-08 | — | — | EP | disclosed |
| WO-2013021343-A1 | PROCESS FOR THE OPTICAL RESOLUTION OF () -3- (2 -BENZYLOXY- 5 - BROMOPHENYL) - 3 - PHENYLPROPIONIC | RANBAXY LABORATORIES LIMITED (IN) | 2013-02-14 | — | — | WO | disclosed |
| US-8338478-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-8338478-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2012-12-25 | — | — | US | disclosed |
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | CURIA SPAIN, S.A.U. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | CURIA SPAIN, S.A.U. (ES) | 2012-08-30 | — | — | US | disclosed |
| US-7985772-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2011-07-26 | — | — | US | disclosed |
| US-7985772-B2 | Derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2011-07-26 | — | — | US | disclosed |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | UCB PHARMA GMBH (DE) | 2006-11-30 | — | — | US | disclosed |
| CN-1690041-A | Novel derivatives of 3,3-diphenylpropylamines | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-11-02 | — | — | CN | disclosed |
| CN-1207268-C | 3, 3-diphenylpropylamine derivatives | SANOL ARZNEI SCHWARZ GMBH (DE) | 2005-06-22 | — | — | CN | disclosed |
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG | 2004-09-23 | — | — | US | disclosed |
| US-6713464-B1 | ANTIMUSCARINIC AGENTS WITH SUPERIOR PHARMACOKINETICS | SCHWARZ PHARMA AG (DE) | 2004-03-30 | — | — | US | disclosed |
| EP-1254890-A1 | Derivatives of 3,3-diphenylpropylamines | SCHWARZ PHARMA AG (DE) | 2002-11-06 | — | — | EP | disclosed |
| EP-1077912-B1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-07-03 | — | — | EP | disclosed |
| CN-1354737-A | Novel 3, 3-diphenylpropylamine derivatives | SANOL ARZNEI SCHWARZ GMBH (DE) | 2002-06-19 | — | — | CN | disclosed |
| EP-1077912-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 2001-02-28 | — | — | EP | disclosed |
| WO-1999058478-A1 | NOVEL DERIVATIVES OF 3,3-DIPHENYLPROPYLAMINES | SCHWARZ PHARMA AG (DE) | 1999-11-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040186061-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | KMT2A 3711/4885SMN1; SMN2 2304/4885LRRK2 3625/4885 |
| US-20060270738-A1 | Novel derivatives of 3,3-diphenylpropylamines | ADRB3, ADRA1D, TNNC1 | KMT2A 3711/4885SMN1; SMN2 2304/4885LRRK2 3625/4885 |
| US-20120220797-A1 | PROCESS FOR OBTAINING 3, 3-DIPHENYLPROPYLAMINES | ADRB3, CHRM3, CYP4F3 | KMT2A 3813/4885SMN1; SMN2 3252/4885LRRK2 802/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.